ACIP Recommendations

Overview

The ACIP develops recommendations on how to use vaccines to control disease in the United States.

The Committee’s recommendations are forwarded to CDC’s Director and once adopted become official CDC policy. These recommendations are then published in CDC’s Morbidity and Mortality Weekly Report (MMWR).

• ACIP Recommendations
  Complete list of ACIP recommendations published in the MMWR.

• Immunization Schedules
  Links to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms.
• VFC Resolutions
  Complete list of vaccines provided by the VFC Program.

• ACIP Shared Clinical Decision-Making FAQs
  Frequently asked questions about ACIP’s recommendations based on shared clinical decision-making

Recent Meeting Recommendations

ACIP approved the following recommendations by majority vote and they have been adopted by the CDC Director. They will be published in MMWR and reflected in CDC’s print and digital resources in the coming months.

October 23-24, 2024

ACIP approved the following recommendations by majority vote at its October 23-24, 2024 meeting:

Pneumococcal Vaccines

ACIP recommends a pneumococcal conjugate vaccine (PCV) for all PCV-naïve adults aged ≥50 years

This recommendation was adopted by the CDC Director on October 23, 2024 and is now official.

COVID-19 Vaccines

In addition to previously recommended 2024-2025 vaccination:

• ACIP recommends a second dose* of 2024-2025 COVID-19 for adults ages 65 years and older
• ACIP recommends a second dose** of 2024-2025 COVID-19 vaccine for people ages 6 months-64 years who are moderately or severely immunocompromised
• ACIP recommends additional doses (i.e., 3 or more doses) of 2024-2025 COVID-19 vaccine for people ages 6 months and older who are moderately or severely immunocompromised under shared clinical decision making

*If previously unvaccinated and receiving Novavax, 2 doses are recommended as initial vaccination series followed by a third dose of any age-appropriate 2024-2025 COVID-19 vaccine 6 months (minimum interval 2 months) after second dose

**If previously unvaccinated or receiving initial vaccination series, at least 2 doses of 2024-2025 vaccine are recommended, and depending on vaccination history more may be needed. This additional 2024-2025 vaccine dose is recommended 6 months (minimum interval 2 months) after completion of initial vaccination series.

These recommendations were adopted by the CDC Director on October 23, 2024 and are now official.

Meningococcal Vaccines

ACIP recommends MenB-4C (Bexsero®) be administered as a 2-dose series at 0 and 6 months when given to healthy adolescents and young adults aged 16–23 years based on shared clinical decision-making for the prevention of serogroup B meningococcal disease

ACIP recommends MenB-4C (Bexsero®) be administered as a 3-dose series at 0, 1–2, and 6 months when given to persons aged ≥10 years at increased risk for serogroup B meningococcal disease (i.e., persons with anatomic or functional asplenia, complement component deficiencies, or complement inhibitor use; microbiologists routinely exposed to N. meningitidis isolates; and persons at increased risk during an outbreak)

These recommendations were adopted by the CDC Director on October 24, 2024 and are now official.

Immunization Schedules

Approve the Recommended Child and Adolescent Immunization Schedule, United States, 2025 and the Recommended Adult Immunization Schedule, United States, 2025.

This recommendation was adopted by the CDC Director on October 24, 2024 and is now official.

February 28-29, 2024

ACIP approved the following recommendation by majority vote at its February 28-29, 2024 meeting:

Chikungunya Vaccine

Recommendations for use of chikungunya vaccine among travelers:

ACIP recommends chikungunya vaccine for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak.

In addition, chikungunya vaccine may be considered for the following persons traveling to a country or territory without an outbreak but with evidence of chikungunya virus transmission among humans within the last 5 years.

• Persons aged >65 years, particularly those with underlying medical conditions, who are likely to have at least moderate exposure* to mosquitoes, OR
• Persons staying for a cumulative period of 6 months or more

*Moderate exposure could include travelers who might have at least 2 weeks (cumulative) of exposure to mosquitoes in indoor or outdoor settings.

Recommendations for use of chikungunya vaccine among laboratory workers:

ACIP recommends chikungunya vaccine for laboratory workers with potential for exposure to chikungunya virus

These recommendations have been adopted by the CDC Director on February 28, 2024 and are now official.

October 25-26, 2023

Mpox Vaccines

ACIP recommends vaccination* with the 2-dose§ JYNNEOS vaccine series for persons aged 18 years and older at risk for mpox¶

*This is an interim recommendation that ACIP will revisit in 2-3 years
§Dose 2 administered 28 days after dose 1
¶Persons at risk:

• Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had one of the following:
  • A new diagnosis of ≥1 sexually transmitted disease
  • More than one sex partner
  • Sex at a commercial sex venue
  • Sex in association with a large public event in a geographic area where mpox transmission is occurring
• Sexual partners of persons with the risks described in above
• Persons who anticipate experiencing any of the above

February 22-24, 2023

ACIP approved the following recommendation by majority vote at its February 22-24, 2023 meeting:

Mpox Vaccines

• ACIP recommends the 2-dose* JYNNEOS vaccine series for persons aged 18 years and older at risk of mpox during an mpox outbreak§.

*Dose 2 administered one month after dose 1
§Public health authorities determine whether there is an mpox outbreak; a single case may be considered an mpox outbreak at the discretion of public health authorities. Other circumstances in which a public health response may be indicated include ongoing risk of introduction of mpox into a community due to disease activity in another geographic area.

This recommendation has been adopted by the CDC Director and is now official.